Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211418 | 0.84 | CHRM2 (0.35) | CHRM2CHRM1CHRM3 | |
| SCHEMBL31080746 | 0.80 | CHRM2 (0.36) | CHRM2CHRM1CHRM3 | |
| SCHEMBL585207 | 0.78 | NR1H3 (0.33) | — | |
| SCHEMBL585010 | 0.78 | NR1H3 (0.33) | — | |
| SCHEMBL352413 | 0.75 | BUB1 (0.33) | CHRM2CHRM1CHRM3 | |
| SCHEMBL1861184 | 0.74 | NR1H2 (0.34) | CHRM2CHRM1CHRM3 | |
| SCHEMBL23902600 | 0.72 | CHRM2 (0.39) | CHRM2CHRM1CHRM3 | |
| SCHEMBL21470687 | 0.72 | CHRM2 (0.39) | CHRM2CHRM1CHRM3 | |
| SCHEMBL8445549 | 0.72 | CHRM2 (0.39) | CHRM2CHRM1CHRM3 | |
| SCHEMBL25489357 | 0.71 | CHRM2 (0.38) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963319-B1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-04-11 | — | — | EP | disclosed |
| US-7618982-B2 | Heteroarylpyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-17 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | MAP3K1, MAP3K19, MAP3K3 | CHRM2 1529/4885CHRM1 1448/4885CHRM3 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.